SPC Financial Inc. Invests $77,000 in Omeros Co. (NASDAQ:OMER)

SPC Financial Inc. bought a new stake in Omeros Co. (NASDAQ:OMER) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,400 shares of the biopharmaceutical company’s stock, valued at approximately $77,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OMER. BNP Paribas Financial Markets grew its stake in Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 12,951 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in Omeros in the 1st quarter worth approximately $85,000. Susquehanna Fundamental Investments LLC purchased a new position in Omeros during the 1st quarter worth approximately $538,000. Vanguard Group Inc. lifted its stake in Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after acquiring an additional 81,348 shares during the period. Finally, Comerica Bank boosted its holdings in shares of Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Performance

Shares of OMER stock opened at $4.14 on Friday. Omeros Co. has a twelve month low of $1.05 and a twelve month high of $5.68. The stock has a market cap of $239.89 million, a P/E ratio of -2.10 and a beta of 1.48. The stock has a 50 day moving average of $3.98 and a 200 day moving average of $3.92.

Omeros (NASDAQ:OMER) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter. On average, research analysts predict that Omeros Co. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Friday, August 16th.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.